Prof Kausik Ray FMedSci
@ProfKausikRay
Immediate Past President EAS, Professor of Public Health, Imperial College London. Cardiologist focusing on preventing coronary artery disease
Obicetrapib is a selective CETPi which ⏬ LDL-C by ~36%. Now in @AmericanHeartJ, we discuss the rational/design of the phase 3 REMBRANDT trial which will examine the effect of obicetrapib + ezetimibe on coronary plaque. sciencedirect.com/science/articl… @JohnKastelein @ProfSNicholls
Published in Atherosclerosis; Our joint editorial by @society_eas EC & the @ATHjournal editorial board — reaffirming the critical need for #sex & #gender integration in ASCVD research & clinical care. 🧬 Sex hormones, chromosomes & social roles all matter. ⚠️ Without this lens,…
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk DOI: 10.1056/NEJMoa2415820 Contributed by Baim faculty: @ProfKausikRay & @ProfSNicholls 👏👏 #Cardiology
ESC late breakers you might be interested in Mon- presented by Jessica Schubert & Steve Nicholls. Sat 5.40 Science Box 5 - independent & joint effects of obesity & metabolic abnormalities on ASCVD, HF, MASLD and ESRD in males & females 1.9 m PY FU
Garden’s looking good. Breakfasts and dinner outside me thinks. Green sanctuary
🧬 ApoB Conformation and LDL Atherogenicity 👉This paper delves into how specific conformational changes in apolipoprotein B-100 impact LDL particle behavior — particularly its binding affinity to arterial wall proteoglycans. These structural transitions increase LDL retention…
#Effect of sotagliflozin on major adverse #cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial thelancet.com/journals/landi… #T2D #CKD #ADA2025
📖 Read the full paper here: 🔗 jacc.org/doi/10.1016/j.… 👏 Huge credit to all INTERASPIRE Investigators for this global contribution to cardiovascular prevention! @ProfKausikRay @johnwmcevoy #LipoproteinA #Lp_a #CVDPrevention #CardioTwitter #Lipidology #JACC #GlobalHealth
#HID2025 What a great panel discussion to close Session 1 on Day 3 of @HeartinDiabetes. Truly the all-stars of CV prevention - great insights & clinical pearls. 🙏🏻 for the positive comments about @FamilyHeartFdn! @BudoffMd @SethShayMartin @DrMarthaGulati @ProfKausikRay @DLBHATTMD
@SethShayMartin presenting at #HiD #heartindiabetes 🫀>than a century of tracking #heartdisease statistics 🫀significant progress made but currently reversing gains we made globally 🫀need more focus on #CVprev #cardiotwitter @ProfKausikRay
INTERASPIRE study coordinated by @NIPCIRELAND @GalwayCMNHS, this nice lp(a) paper led by great collaborator and Executive Committee member @ProfKausikRay
The vast majority of patients with #CHD have Lp(a) levels far below what is considered a typical risk-enhancing threshold, suggesting that the attributable risk from Lp(a) is more complex than previously perceived. Learn more: bit.ly/43lbEMP #JACC @JACCJournals
Great to be at @nationallipid with @ProfKausikRay Great science with good friends! @society_eas
The best way to treat atherosclerosis is to prevent it. @ProfKausikRay @nationallipid #NLASessions @CBallantyneMD @lipidcns